Advertisement

Breast Cancer Research and Treatment

, Volume 97, Issue 3, pp 263–274 | Cite as

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells

  • Stephen HiscoxEmail author
  • Liam Morgan
  • Tim P. Green
  • Denise Barrow
  • Julia Gee
  • Robert I. Nicholson
Preclinical study

Summary

Src kinase plays a central role in growth factor signalling, regulating a diverse array of cellular functions including proliferation, migration and invasion. Recent studies have demonstrated that Src activity is frequently elevated in human tumours and correlates with disease stage. We have previously demonstrated that, upon acquisition of tamoxifen resistance, MCF7 cells display increased epidermal growth factor receptor (EGFR) activation and a more aggressive phenotype in vitro. Since tumours exhibiting elevated EGFR signalling may possess elevated levels of Src activity, we wished to investigate the role of Src in our MCF7 model of endocrine resistance. Src kinase activity was significantly elevated in tamoxifen-resistant (TamR) cells in comparison to wild type MCF7 cells. This increase was not due to elevated Src protein or gene expression. Treatment of TamR cells with the novel Src inhibitor, AZD0530, significantly reduced the amount of activated Src detectable in both cell types whilst having no effect on total Src levels. AZD0530 significantly suppressed the motile and invasive nature of TamR cells in vitro, reduced basal levels of activated focal adhesion kinase (FAK) and paxillin and promoted elongation of focal adhesions. Furthermore, the use of this compound in conjunction with the EGFR inhibitor, gefitinib, was markedly additive towards inhibition of TamR cell motility and invasion. These observations suggest that Src plays a pivotal role in mediating the motile and invasive phenotype observed in endocrine-resistant breast cancer cells. The use of Src inhibitors in conjunction with EGFR inhibitors such as gefitinib may provide an effective method with which to prevent cancer progression and metastasis.

Keywords

breast cancer endocrine-resistance invasion motility Src 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

The authors wish to thank Carol Dutkowski, Huw Mottram, Lucy Green and Alastair Wilson for their expert technical contributions to this project.

References

  1. 1.
    Kurebayashi J, Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance Breast Cancer 10: 112–119, 2003PubMedCrossRefGoogle Scholar
  2. 2.
    Schiff R, Massarweh S, Shou J, Osborne CK, Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response Clin Cancer Res 9: 447–454, 2003Google Scholar
  3. 3.
    Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI, Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144: 1032–1044, 2003CrossRefPubMedGoogle Scholar
  4. 4.
    Hiscox SE, Morgan L, Barrow D, Dutkowski C, Nicholson RI, Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib (‘Iressa’ ZD1839) Clin Exp Met 21: 213–221, 2004CrossRefGoogle Scholar
  5. 5.
    Baselga J, Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 7: 2–8, 2002PubMedCrossRefGoogle Scholar
  6. 6.
    El-Rayes BF, LoRusso PM, Targeting the epidermal growth factor receptor Br J Cancer 91: 418–424, 2004CrossRefPubMedGoogle Scholar
  7. 7.
    Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW, Epidermal growth factor receptor: mechanisms of activation and signalling Exp Cell Res 284: 31–53, 2003CrossRefPubMedGoogle Scholar
  8. 8.
    Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ, c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function J Biol Chem 274: 8335–8343, 1999PubMedCrossRefGoogle Scholar
  9. 9.
    Leu TH, Maa MC, Functional implication of the interaction between EGF receptor and c-Src Front Biosci 8: s28–38, 2003PubMedCrossRefGoogle Scholar
  10. 10.
    Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ, Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity Mol Cell Biol 14: 735–743, 1994PubMedGoogle Scholar
  11. 11.
    Wilson LK, Luttrell DK, Parsons JT, Parsons SJ, pp60c-src tyrosine kinase myristylation and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src Mol Cell Biol 9: 1536–1544, 1989PubMedGoogle Scholar
  12. 12.
    Roche S, Koegl M, Barone MV, Roussel MF, Courtneidge SA, DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases Mol Cell Biol 15: 1102–1109, 1995PubMedGoogle Scholar
  13. 13.
    Tice DA, Biscardi JS, Nickles AL, Parsons SJ, Mechanism of biological synergy between cellular Src and epidermal growth factor receptor Proc Natl Acad Sci USA 96: 1415–1420, 1999PubMedCrossRefGoogle Scholar
  14. 14.
    Maa MC, Leu TH, McCarley DJ, Schatzman RC, Parsons SJ, Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers Proc Natl Acad Sci USA 92: 6981–6985, 1995PubMedCrossRefGoogle Scholar
  15. 15.
    Biscardi JS, Belsches AP, Parsons SJ, Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells Mol Carcinog 21: 261–272, 1998CrossRefPubMedGoogle Scholar
  16. 16.
    Schwartzberg PL, Xing L, Hoffmann O, Lowell CA, Garrett L, Boyce BF, Varmus HE, Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice Genes Dev 11: 2835–2844, 1997PubMedCrossRefGoogle Scholar
  17. 17.
    Kaplan KB, Swedlow JR, Morgan DO, Varmus HE, c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism Genes Dev 9:1505–1517, 1995PubMedCrossRefGoogle Scholar
  18. 18.
    Fincham VJ, Frame MC, The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility Embo J 17: 81–92, 1998CrossRefPubMedGoogle Scholar
  19. 19.
    Jones RJ, Avizienyte E, Wyke AW, Owens DW, Brunton VG, Frame MC, Elevated c-Src is linked to altered cell–matrix adhesion rather than proliferation in KM12C human colorectal cancer cells Br J Cancer 87: 1128–1135, 2002CrossRefPubMedGoogle Scholar
  20. 20.
    Irby RB, Yeatman TJ, Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells Cancer Res 62: 2669–2674, 2004Google Scholar
  21. 21.
    Boyer B, Roche S, Denoyelle M, Thiery JP, Src and Ras are involved in separate pathways in epithelial cell scattering Embo J 16: 5904–5913, 1997CrossRefPubMedGoogle Scholar
  22. 22.
    Boyer B, Bourgeois Y, Poupon MF, Src kinase contributes to the metastatic spread of carcinoma cells Oncogene 21: 2347–2356, 2002CrossRefPubMedGoogle Scholar
  23. 23.
    Masaki T, Okada M, Shiratori Y, Rengifo W, Matsumoto K, Maeda S, Kato N, Kanai F, Komatsu Y, Nishioka M, Omata M, pp60c-src activation in hepatocellular carcinoma of humans and LEC rats Hepatology 27: 1257–1264, 1998CrossRefPubMedGoogle Scholar
  24. 24.
    Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, Li JQ, Yoneyama H, Uchida N, Fujita J, Yoshiji H, Watanabe S, Kurokohchi K, Kuriyama S, pp60c-src activation in lung adenocarcinoma Eur J Cancer 39: 1447–1455, 2003CrossRefPubMedGoogle Scholar
  25. 25.
    Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE, Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers Gynecol Oncol 88: 73–79, 2003CrossRefPubMedGoogle Scholar
  26. 26.
    Summy JM, Gallick GE, Src family kinases in tumor progression and metastasis Cancer Metastasis Rev 22: 337–358, 2003CrossRefPubMedGoogle Scholar
  27. 27.
    Ple PA, Green TP, Hennequin LF, Curwen J, Fennell M, Allen J, Lambert-Van Der Brempt C, Costello G, Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src J Med Chem 47: 871–887, 2004CrossRefPubMedGoogle Scholar
  28. 28.
    Yeatman TJ, 2004 A renaissance for SRC Nat Rev Cancer 4: 470–480CrossRefPubMedGoogle Scholar
  29. 29.
    Hanks SK, Ryzhova L, Shin NY, Brabek J, Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility Front Biosci 8: d982–996, 2003PubMedCrossRefGoogle Scholar
  30. 30.
    Turner CE, 2000 Paxillin interactions J Cell Sci 113: 4139–4140PubMedGoogle Scholar
  31. 31.
    Frame MC, 2002 Src in cancer: deregulation and consequences for cell behaviour Biochim Biophys Acta 1602: 114–130PubMedGoogle Scholar
  32. 32.
    Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE, Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis Cancer 94: 344–351, 2002CrossRefPubMedGoogle Scholar
  33. 33.
    Ito Y, Kawakatsu H, Takeda T Tani N, Kawaguchi N, Noguchi S, Sakai T, Matsuura N, Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma Breast Cancer Res Treat 76: 261–267, 2002CrossRefPubMedGoogle Scholar
  34. 34.
    Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J, Yu H, Garcia R, Jove R, Yeatman TJ, Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential Oncogene 15: 3083–3090, 1997CrossRefPubMedGoogle Scholar
  35. 35.
    Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT, pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions Proc Natl Acad Sci USA89: 5192–5196, 1992PubMedCrossRefGoogle Scholar
  36. 36.
    Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT, Autophosphorylation of the focal adhesion kinase pp125FAK directs SH2-dependent binding of pp60src Mol Cell Biol 14: 1680–1688, 1994PubMedGoogle Scholar
  37. 37.
    Schlaepfer DD, Mitra SK, Ilic D, Control of motile and invasive cell phenotypes by focal adhesion kinase Biochim Biophys Acta 1692: 77–102, 2004PubMedGoogle Scholar
  38. 38.
    Bellis SL, Miller JT, Turner CE, Characterization of tyrosine phosphorylation of paxillin in vitro by focal adhesion kinase J Biol Chem 270: 17437–17441, 1995PubMedGoogle Scholar
  39. 39.
    Petit V, Boyer B, Lentz D, Turner CE, Thiery JP, Valles AM, Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells J Cell Biol 148: 957–970, 2000CrossRefPubMedGoogle Scholar
  40. 40.
    Romanova LY, Hashimoto S, Chay KO, Blagosklonny MV, Sabe H, Mushinski JF, Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive J Cell Sci 117: 3759–3768, 2004CrossRefPubMedGoogle Scholar
  41. 41.
    Gilmore AP, Romer LH, Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation Mol Biol Cell 7: 1209–1224, 1996PubMedGoogle Scholar
  42. 42.
    Sieg DJ, Hauck CR, Schlaepfer DD, Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration J Cell Sci 112: 2677–2691, 1999PubMedGoogle Scholar
  43. 43.
    Owen JD, Ruest PJ, Fry DW, Hanks SK, Induced focal adhesion kinase (FAK) expression in FAK-null cells enhances cell spreading and migration requiring both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2 Mol Cell Biol 19: 4806–4818, 1999PubMedGoogle Scholar
  44. 44.
    Klinghoffer RA, Sachsenmaier C, Cooper JA, Soriano P, Src family kinases are required for integrin but not PDGFR signal transduction Embo J 18: 2459–71, 1999CrossRefPubMedGoogle Scholar
  45. 45.
    Pories SE, Hess DT, Swenson K, Lotz M, Moussa R, Steele G, Jr, Shibata D, Rieger-Christ KM, Summerhayes C, Overexpression of pp60c-src elicits invasive behavior in rat colon epithelial cells Gastroenterology 114: 1287–1295, 1998CrossRefPubMedGoogle Scholar
  46. 46.
    Sato K, Nagao T, Iwasaki T, Nishihira Y, Fukami Y, Src-dependent phosphorylation of the EGF receptor Tyr-845 mediates Stat-p21waf1 pathway in A431 cells Genes Cells 8: 995–1003, 2003CrossRefPubMedGoogle Scholar
  47. 47.
    Moro L, Dolce L, Cabodi S, Bergatto E, Erba EB, Smeriglio M, Turco E, Retta SF, Giuffrida MG, Venturino M, Godovac-Zimmermann J, Conti A, Schaefer E, Beguinot L, Tacchetti C, Gaggini P, Silengo L, Tarone G, Defilippi P, Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines J Biol Chem 277: 9405–9414, 2002CrossRefPubMedGoogle Scholar
  48. 48.
    Boerner JL, Demory ML, Silva C, Parsons SJ, Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II Mol Cell Biol 24: 7059–7071, 2004CrossRefPubMedGoogle Scholar
  49. 49.
    Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, Silva CM, STAT5b a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor J Biol Chem 278: 1671–1679, 2003CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Stephen Hiscox
    • 1
    Email author
  • Liam Morgan
    • 1
  • Tim P. Green
    • 2
  • Denise Barrow
    • 1
  • Julia Gee
    • 1
  • Robert I. Nicholson
    • 1
  1. 1.Tenovus Centre for Cancer ResearchWelsh School of PharmacyCardiffUK
  2. 2.AstraZeneca PharmaceuticalsMacclesfieldUK

Personalised recommendations